Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05201066




Registration number
NCT05201066
Ethics application status
Date submitted
3/01/2022
Date registered
21/01/2022
Date last updated
21/05/2025

Titles & IDs
Public title
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Scientific title
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Secondary ID [1] 0 0
CMBG453B12206B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelodysplastic Syndromes 0 0
Leukemia, Myelomonocytic, Chronic 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - decitabine
Treatment: Drugs - spartalizumab
Treatment: Drugs - sabatolimab
Treatment: Drugs - azacitidine
Treatment: Drugs - venetoclax
Treatment: Drugs - INQOVI (oral decitabine)

Experimental: sabatolimab + azacitidine - Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w.

Experimental: sabatolimab + decitabine - Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v.

Experimental: sabatolimab + venetoclax + azacitidine - Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w.

Experimental: sabatolimab + spartalizumab + decitabine - Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w.

Experimental: sabatolimab + HMA - Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w

HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine.

Experimental: sabatolimab - Patients will take sabatolimab 800 mg i.v q4w.


Treatment: Drugs: decitabine
Solution for intravenous infusion

Treatment: Drugs: spartalizumab
Solution for intravenous infusion

Treatment: Drugs: sabatolimab
Solution for intravenous infusion

Treatment: Drugs: azacitidine
Solution for subcutaneous injection or intravenous infusion

Treatment: Drugs: venetoclax
Tablet for oral administration

Treatment: Drugs: INQOVI (oral decitabine)
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [1] 0 0
5 years
Primary outcome [2] 0 0
Severity of AEs and SAEs
Timepoint [2] 0 0
5 years
Secondary outcome [1] 0 0
Duration of exposure to sabatolimab
Timepoint [1] 0 0
5 years

Eligibility
Key inclusion criteria
1. Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
2. Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
3. Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
4. Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
5. Written informed consent obtained prior to enrolling in the roll-over study.
Minimum age
12 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
2. Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
3. Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
4. Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
5. Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
6. Local access to commercially available sabatolimab for parent protocol indications.

Other protocol-defined Inclusion/Exclusion may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/02/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
14/02/2028
Actual
Sample size
Target
Accrual to date
Final
33
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Clayton
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Oregon
Country [3] 0 0
United States of America
State/province [3] 0 0
Utah
Country [4] 0 0
Brazil
State/province [4] 0 0
SC
Country [5] 0 0
Canada
State/province [5] 0 0
British Columbia
Country [6] 0 0
China
State/province [6] 0 0
Jilin
Country [7] 0 0
China
State/province [7] 0 0
Tianjin
Country [8] 0 0
Czechia
State/province [8] 0 0
Praha
Country [9] 0 0
France
State/province [9] 0 0
Toulouse
Country [10] 0 0
Germany
State/province [10] 0 0
Freiburg
Country [11] 0 0
Greece
State/province [11] 0 0
Evros
Country [12] 0 0
Greece
State/province [12] 0 0
Patras
Country [13] 0 0
Italy
State/province [13] 0 0
BS
Country [14] 0 0
Italy
State/province [14] 0 0
FI
Country [15] 0 0
Italy
State/province [15] 0 0
GE
Country [16] 0 0
Italy
State/province [16] 0 0
MI
Country [17] 0 0
Italy
State/province [17] 0 0
RM
Country [18] 0 0
Japan
State/province [18] 0 0
Fukushima
Country [19] 0 0
Malaysia
State/province [19] 0 0
Kuala Lumpur
Country [20] 0 0
Spain
State/province [20] 0 0
Catalunya
Country [21] 0 0
Spain
State/province [21] 0 0
Madrid
Country [22] 0 0
Switzerland
State/province [22] 0 0
Zuerich
Country [23] 0 0
Turkey
State/province [23] 0 0
Izmir

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05201066